Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/105922
PIRA download icon_1.1View/Download Full Text
DC FieldValueLanguage
dc.contributorDepartment of Health Technology and Informatics-
dc.creatorCheung, AHK-
dc.creatorTsui, NBY-
dc.creatorCho, WCS-
dc.creatorPei, XM-
dc.creatorWong, YKE-
dc.creatorTsang, HFA-
dc.creatorLeung, GKK-
dc.creatorWong, SCC-
dc.date.accessioned2024-04-23T04:32:20Z-
dc.date.available2024-04-23T04:32:20Z-
dc.identifier.urihttp://hdl.handle.net/10397/105922-
dc.language.isoenen_US
dc.publisherLIDSEN Publishing Inc.en_US
dc.rights© 2020 by the author. This is an open access article distributed under the conditions of the Creative Commons by Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.en_US
dc.rightsThe following publication Cheung AHK, Tsui NBY, Cho WCS, Pei XM, Wong YKE, Tsang HFA, Leung GKK, Wong SCC. Genetic Variants of Targetable Cancer-related Genes in Vestibular Schwannomas. OBM Genetics 2020; 4(2): 112 at available at https://doi.org/10.21926/obm.genet.2002112.en_US
dc.subjectGenetic variantsen_US
dc.subjectTargeted DNA sequencingen_US
dc.subjectTargeted therapyen_US
dc.subjectVestibular schwannomaen_US
dc.titleGenetic variants of targetable cancer-related genes in vestibular schwannomasen_US
dc.typeJournal/Magazine Articleen_US
dc.identifier.volume4-
dc.identifier.issue2-
dc.identifier.doi10.21926/obm.genet.2002112-
dcterms.abstractBackground: Vestibular schwannoma is an intracranial tumor which can lead to devastating neurological deficit and is prone to recurrence after surgery. Patients with inherited neurofibromatosis type 2 (NF2) syndrome are particularly susceptible to bilateral and aggressive schwannomas. However, the genome of vestibular schwannomas is not well known. There is an imminent need of developing effective chemotherapeutic agents either as a primary treatment modality or as adjuvant therapy for these patients.-
dcterms.abstractMethods: Here, we subjected both sporadic and NF2-related schwannomas to high-throughput DNA sequencing using a panel of therapeutically important cancer-related genes, in order to determine if targetable genetic changes are present in schwannomas.-
dcterms.abstractResults: A number of variants were detected in the genes NRAS, PDGFRA, KIT, and EGFR, in both sporadic and NF2-related cases. The results were confirmed by Sanger sequencing.-
dcterms.abstractConclusion: Our study successfully detected some genetic variants in important cancer-related genes in schwannomas, and further elucidation of their relationship to drug-response will be pursued.-
dcterms.accessRightsopen accessen_US
dcterms.bibliographicCitationOBM genetics, June 2020, v. 4, no. 2, 112-
dcterms.isPartOfOBM genetics-
dcterms.issued2020-06-
dc.identifier.scopus2-s2.0-85150711465-
dc.identifier.eissn2577-5790-
dc.identifier.artn112-
dc.description.validate202404 bcch-
dc.description.oaVersion of Recorden_US
dc.identifier.FolderNumberOA_Scopus/WOSen_US
dc.description.fundingSourceSelf-fundeden_US
dc.description.pubStatusPublisheden_US
dc.description.oaCategoryCCen_US
Appears in Collections:Journal/Magazine Article
Files in This Item:
File Description SizeFormat 
obm.genet.2002112.pdf452.45 kBAdobe PDFView/Open
Open Access Information
Status open access
File Version Version of Record
Access
View full-text via PolyU eLinks SFX Query
Show simple item record

Page views

9
Citations as of Jun 30, 2024

Downloads

3
Citations as of Jun 30, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.